Skip to main content

Table 1 Comparison of the baseline demographics between 2001–2005 and 2006–2010 in patients with pancreatic cancer (n = 1,082)

From: Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients

  Total 2001–2005 2006–2010 P-value
Age (y) 71.5 ± 10.9 71.0 ± 10.4 71.8 ± 11.2 0.24911
Sex (Male/Female) 566/516 210/196 356/320 0.76472
Stage I 22 (2.0%) 10 (2.5%) 12 (1.8%) 0.43762
II 37 (3.4%) 13 (3.2%) 24 (3.6%) 0.76022
III 141 (13.0%) 46 (11.3%) 95 (14.0%) 0.19762
IVa 288 (26.6%) 113 (27.8%) 175 (25.9%) 0.48342
IVb 594 (54.9%) 224 (55.2%) 370 (54.7%) 0.88832
Treatment Surgery 187 (17.3%) 64 (15.8%) 123 (18.2%) 0.30572
Chemotherapy 519 (48.0%) 172 (42.4%) 347 (51.3%) <0.00012
BSC/RT 376 (34.8%) 170 (41.9%) 206 (30.5%) 0.00042
Cause of death 654/31 274/12 380/19 0.72522
PC related/PC unrelated     
  1. BSC, best supportive care; RT, radiation therapy; PC, pancreatic cancer.
  2. 1Student’s t-test; 2chi square test.